Serum free light chains and multiple myeloma: Is it time to extend their application?
Abstract In nonsecretory, oligo‐secretory, and light chain multiple myeloma patients, serial sFLC evaluation could precede biochemical and clinical disease progression, even in extramedullary relapse, thus initiating early treatment with novel anti‐MM agents.
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-04-01
|
| Series: | Clinical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ccr3.2636 |
| id |
doaj-657fa85075444633b56e89ba4c07bb88 |
|---|---|
| record_format |
Article |
| spelling |
doaj-657fa85075444633b56e89ba4c07bb882020-11-25T01:48:01ZengWileyClinical Case Reports2050-09042020-04-018461762410.1002/ccr3.2636Serum free light chains and multiple myeloma: Is it time to extend their application?Uros Markovic0Valerio Leotta1Daniele Tibullo2Rachele Giubbolini3Alessandra Romano4Vittorio Del Fabro5Nunziatina Laura Parrinello6Maria Teresa Cannizzaro7Francesco Di Raimondo8Concetta Conticello9UOC di Ematologia con Trapianto di Midollo Osseo AOU "Policlinico‐Vittorio Emanuele” Catania ItalyUOC di Ematologia con Trapianto di Midollo Osseo AOU "Policlinico‐Vittorio Emanuele” Catania ItalyDepartment of Biomedical and Biotechnological Sciences University of Catania Catania ItalyUOC di Ematologia con Trapianto di Midollo Osseo AOU "Policlinico‐Vittorio Emanuele” Catania ItalyUOC di Ematologia con Trapianto di Midollo Osseo AOU "Policlinico‐Vittorio Emanuele” Catania ItalyUOC di Ematologia con Trapianto di Midollo Osseo AOU "Policlinico‐Vittorio Emanuele” Catania ItalyUOC di Ematologia con Trapianto di Midollo Osseo AOU "Policlinico‐Vittorio Emanuele” Catania ItalyRadiology via Santa Sofia 78 AOU Policlinico‐"Vittorio Emanuele" Catania ItalyUOC di Ematologia con Trapianto di Midollo Osseo AOU "Policlinico‐Vittorio Emanuele” Catania ItalyUOC di Ematologia con Trapianto di Midollo Osseo AOU "Policlinico‐Vittorio Emanuele” Catania ItalyAbstract In nonsecretory, oligo‐secretory, and light chain multiple myeloma patients, serial sFLC evaluation could precede biochemical and clinical disease progression, even in extramedullary relapse, thus initiating early treatment with novel anti‐MM agents.https://doi.org/10.1002/ccr3.2636disease progressionextramedullary relapsemultiple myelomaserological markersserum free light chains |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Uros Markovic Valerio Leotta Daniele Tibullo Rachele Giubbolini Alessandra Romano Vittorio Del Fabro Nunziatina Laura Parrinello Maria Teresa Cannizzaro Francesco Di Raimondo Concetta Conticello |
| spellingShingle |
Uros Markovic Valerio Leotta Daniele Tibullo Rachele Giubbolini Alessandra Romano Vittorio Del Fabro Nunziatina Laura Parrinello Maria Teresa Cannizzaro Francesco Di Raimondo Concetta Conticello Serum free light chains and multiple myeloma: Is it time to extend their application? Clinical Case Reports disease progression extramedullary relapse multiple myeloma serological markers serum free light chains |
| author_facet |
Uros Markovic Valerio Leotta Daniele Tibullo Rachele Giubbolini Alessandra Romano Vittorio Del Fabro Nunziatina Laura Parrinello Maria Teresa Cannizzaro Francesco Di Raimondo Concetta Conticello |
| author_sort |
Uros Markovic |
| title |
Serum free light chains and multiple myeloma: Is it time to extend their application? |
| title_short |
Serum free light chains and multiple myeloma: Is it time to extend their application? |
| title_full |
Serum free light chains and multiple myeloma: Is it time to extend their application? |
| title_fullStr |
Serum free light chains and multiple myeloma: Is it time to extend their application? |
| title_full_unstemmed |
Serum free light chains and multiple myeloma: Is it time to extend their application? |
| title_sort |
serum free light chains and multiple myeloma: is it time to extend their application? |
| publisher |
Wiley |
| series |
Clinical Case Reports |
| issn |
2050-0904 |
| publishDate |
2020-04-01 |
| description |
Abstract In nonsecretory, oligo‐secretory, and light chain multiple myeloma patients, serial sFLC evaluation could precede biochemical and clinical disease progression, even in extramedullary relapse, thus initiating early treatment with novel anti‐MM agents. |
| topic |
disease progression extramedullary relapse multiple myeloma serological markers serum free light chains |
| url |
https://doi.org/10.1002/ccr3.2636 |
| work_keys_str_mv |
AT urosmarkovic serumfreelightchainsandmultiplemyelomaisittimetoextendtheirapplication AT valerioleotta serumfreelightchainsandmultiplemyelomaisittimetoextendtheirapplication AT danieletibullo serumfreelightchainsandmultiplemyelomaisittimetoextendtheirapplication AT rachelegiubbolini serumfreelightchainsandmultiplemyelomaisittimetoextendtheirapplication AT alessandraromano serumfreelightchainsandmultiplemyelomaisittimetoextendtheirapplication AT vittoriodelfabro serumfreelightchainsandmultiplemyelomaisittimetoextendtheirapplication AT nunziatinalauraparrinello serumfreelightchainsandmultiplemyelomaisittimetoextendtheirapplication AT mariateresacannizzaro serumfreelightchainsandmultiplemyelomaisittimetoextendtheirapplication AT francescodiraimondo serumfreelightchainsandmultiplemyelomaisittimetoextendtheirapplication AT concettaconticello serumfreelightchainsandmultiplemyelomaisittimetoextendtheirapplication |
| _version_ |
1725013448163590144 |